“…They are most likely with the first treatment (Orange et al, 2006) and increasing doses and infusion rate (Struff, Klasser, Eckert, & Dietrich, 2005). IVIg was tolerated well with only one patient reporting a slight headache (Adam et al, 2015;Aichelburg et al, 2012;Barde et al, 2009;Eastham et al, 2014). Severe adverse events are rare but may include anaphylaxis, hypotension, aseptic meningitis, thromboembolic events, or acute renal failure (Cherin et al, 2016;Orange et al, 2006).…”